GLP-1 Mimetic clinical trials
A group of medicines. Semaglutide (451 studies) is counted on its own page; this page counts the studies that name GLP-1 Mimetic itself.
How each study uses GLP-1 Mimetic is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the GLP-1 Mimetic studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Medicines filed under GLP-1 Mimetic
As reviewed, so not every one. Each counts its studies on its own page, not here.
Studies by the year they started
19 studies that test it; most in 2020 (4); 1 more planned to start later
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 1 |
| 2022 | 2 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 17
The Affiliated Hospital of Xuzhou Medical University (2) · PegBio Co., Ltd. (2) · Peking University Third Hospital (2) · Lia Bally (1) · GRADE Study Group (1) · Tanabe Pharma Corporation (1) · Sciwind Biosciences APAC CO Pty. Ltd. (1) · Kowa Company, Ltd. (1)
Often tested with
Tested in the same studies.
Semaglutide (5) · SGLT2 inhibitors (2) · Hormone Replacement Therapy (1) · Glimepiride (1) · Sitagliptin (1) · Insulin Glargine (1) · Canagliflozin (1) · Tofogliflozin (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test GLP-1 Mimetic.
- Dec 2026Menopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Overweight/Obesity and Impaired Glucose HomeostasisNot applicable · Lia Bally
- Dec 2026Effects of GLP-1RAs on Reproductive Outcomes in PCOS and ObesityNot applicable · Peking University Third Hospital
- May 2027GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)Phase 2 · Chinese University of Hong Kong
Studies
Open first, then newest update. How each study uses GLP-1 Mimetic is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 20
- Effects of GLP-1RAs on Fertility Outcomes in Obese Women With PCOSRecruitingNot applicablePeking University Third HospitalNCT07687667Written as GLP-1 receptor agonistHow we know
- Impact GLP-1 Agonists Following BariatricRecruitingPhase 4University of Missouri-ColumbiaNCT06132477Written as GLP-1 receptor agonistHow we know
- SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial CancerNot yet recruitingPhase 4Hospital Universitari de BellvitgeNCT07462663Written as GLP-1 Receptor AgonistHow we know
- GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)RecruitingPhase 2Chinese University of Hong KongNCT05356104Written as GLP-1 receptor agonistHow we know
- Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist TherapyRecruitingPhase 2University of VirginiaNCT06903923Written as GLP-1 receptor agonistHow we know
- PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 DiabetesRecruitingPhase 4Brigham and Women's HospitalNCT05390892Written as GLP-1 receptor agonistHow we know
- Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal CancerNot yet recruitingPhase 2St. James's Hospital, IrelandNCT07314528Written as GLP-1 receptor agonistHow we know
- Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DMRecruitingNot applicableThe Affiliated Hospital of Xuzhou Medical UniversityNCT06256419Written as GLP-1 receptor agonistHow we know
- Effects of GLP-1RAs on Reproductive Outcomes in PCOS and ObesityNot yet recruitingNot applicablePeking University Third HospitalNCT06775093Written as GLP-1 receptor agonistHow we know
- Menopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Overweight/Obesity and Impaired Glucose HomeostasisActive, not recruitingNot applicableLia BallyNCT06715514Written as GLP-1 Receptor AgonistHow we know
- A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 DiabetesCompletedPhase 3GRADE Study GroupNCT01794143Written as GLP-1 receptor agonist (liraglutide)How we know
- Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes MellitusCompletedPhase 4Tanabe Pharma CorporationNCT02227849Written as GLP-1 analogueHow we know
- Effect of GLP-1 Receptor Agonists on Trabecular Bone ScoreTerminatedPhase 2University of Mississippi Medical CenterNCT04964388Written as GLP-1 receptor agonistHow we know
- Effect of Gene Polymorphisms on GLP-1 Receptor Agonists Response in Patients With T2DMCompletedNot applicableThe Affiliated Hospital of Xuzhou Medical UniversityNCT05037045Written as GLP-1 receptor agonistHow we know
- Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin MonotherapyCompletedPhase 3PegBio Co., Ltd.NCT04504396Written as GLP-1 receptor agonistHow we know
- Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM SubjectsCompletedPhase 3PegBio Co., Ltd.NCT04504370Written as GLP-1 receptor agonistHow we know
- To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult ParticipantsCompletedPhase 1Sciwind Biosciences APAC CO Pty. Ltd.NCT04389775Written as Cohort AHow we know
- Tofogliflozin GLP-1 Analogue Combination TrialCompletedPhase 4Kowa Company, Ltd.NCT02537834Written as GLP-1 analogueHow we know
- Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?CompletedNot applicableUniversity of California, San FranciscoNCT02846233Written as GLP1 receptor agonistHow we know
- Relationship Between Improvement in Insulin Secretion and Decrease in HbA1c in GLP-1 RA Therapy in T2DM PatientsStatus unknownPhase 4Dasman Diabetes InstituteNCT04135287Written as GLP-1 receptor agonistHow we know
Given beside what is tested · 1 — GLP-1 Mimetic is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with GLP-1 Mimetic
What changed recently
From the registry's own updates since Oct 20, 2026.
Started recruiting1
- Effects of GLP-1RAs on Fertility Outcomes in Obese Women With PCOSNov 17, 2026NCT07687667